NCT05134363View on ClinicalTrials.gov

Dexmedetomidine for Prophylaxis Against PONV in Highly Susceptible Patients.

NACompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

June 20, 2023

Study Completion Date

June 20, 2023

Conditions
Postoperative Nausea and VomitingHead and Neck Surgeries
Interventions
DRUG

Dexmedetomidine Hydrochloride 0.5 mic/kg bolus

comparison between two bolus doses of dexmedetomidine with a placebo group

DRUG

Dexmedetomidine Hydrochloride 0.75 mic/kg bolus

comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.

DRUG

Placebo

equal volume of normal saline

Trial Locations (1)

11511

Cairo University, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT05134363 - Dexmedetomidine for Prophylaxis Against PONV in Highly Susceptible Patients. | Biotech Hunter | Biotech Hunter